UK MHRA Finds Labs Releasing Unreliable Data Due To Pressure From Pharma
Executive Summary
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
You may also be interested in...
UK Explains Dos and Don’ts Of Adaptive Clinical Trials
Adaptive clinical trials offer several benefits, but they require effective management to be successful, says a senior inspector at the UK’s medicines regulator.
Global Medtech Guidance Tracker: February 2021
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: